Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects

Molecular Cancer Therapeutics
Sulma I MohammedDeborah W Knapp

Abstract

More than 14,000 people die from invasive transitional cell carcinoma (TCC) of the urinary bladder yearly in the United States. Cyclooxygenase (COX)-inhibiting drugs are emerging as potential antitumor agents in TCC. The optimal in vitro or in vivo systems to investigate COX inhibitor antitumor effects have not been defined. The purpose of this study was to determine COX-1 and COX-2 expression and antitumor effects of COX inhibitors in human TCC cell lines (HT1376, RT4, and UMUC3 cells) and xenografts derived from those cell lines. COX-2 expression (Western blot, immunocytochemistry) was high in HT1376, modest in RT4, and absent in UMUC3 cells in vitro. Similarly, COX-2 expression was noted in RT4 but not UMUC3 xenografts. COX-2 expression in HT1376 xenografts was slightly lower than that observed in vitro. None of four COX inhibitors evaluated (celecoxib, piroxicam, valeryl salicylate, and NS398) reduced TCC growth in standard in vitro proliferation assays at concentrations that could be safely achieved in vivo (< or =5 micromol/L). Higher celecoxib concentrations (> or =50 micromol/L) inhibited proliferation and induced apoptosis in all three cell lines. Celecoxib or piroxicam treatment in athymic mice significantly delayed p...Continue Reading

References

Jul 1, 1994·Journal of Veterinary Internal Medicine·D W KnappT Kuczek
Dec 2, 1999·JAMA : the Journal of the American Medical Association·M J LangmanT J Simon
May 10, 2000·American Journal of Veterinary Research·K N KhanR K Harris
Mar 10, 2001·The American Journal of Pathology·A RistimäkiC Haglund
Mar 30, 2001·The Journal of Biological Chemistry·C H LiuT Hla
Jun 12, 2002·Current Treatment Options in Oncology·R Dreicer
Dec 5, 2002·Journal of the National Cancer Institute·Jiuxiang ZhuChing-Shih Chen
Apr 10, 2003·Journal of Veterinary Internal Medicine·Anthony J MutsaersDeborah W Knapp
May 15, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·David W J ClarkSaad A W Shakir
Mar 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manish I PatelAndrew J Dannenberg

❮ Previous
Next ❯

Citations

Aug 2, 2012·American Journal of Veterinary Research·Joao Felipe de Brito GalvaoNongnuch Inpanbutr
Sep 2, 2011·Cancer Prevention Research·Anita L SabichiSeth P Lerner
Jul 1, 2008·Expert Review of Anticancer Therapy·John A TaylorAndrew Nisbet
Mar 29, 2014·Expert Opinion on Drug Discovery·Paula A OliveiraCarmen Vasconcelos-Nóbrega
Nov 18, 2008·Expert Opinion on Investigational Drugs·Alexandros LekasAndreas C Lazaris
May 17, 2015·Ultrasonics·Manasi DahibawkarFlemming Forsberg
May 1, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Luigi RossielloRaffaele Rossiello
Aug 19, 2011·Veterinary and Comparative Oncology·K Sonzogni-DesautelsM Doré
Sep 30, 2010·Veterinary Pathology·M Doré
Jul 5, 2007·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Kenneth M Rassnick, Bradley L Njaa
Jun 2, 2018·The Journal of Urology·Timothy D LyonStephen A Boorjian
Dec 19, 2006·Molecular Cancer Therapeutics·Antonio JimenoManuel Hidalgo
Jan 14, 2020·Prostaglandins & Other Lipid Mediators·Benjamin L WoolbrightJohn A Taylor
Aug 21, 2013·Journal of Cell Science·Ron C J SchackmannPatrick W B Derksen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis